Halozyme Therapeutics Inc (Halozyme) is a biotechnology company, which focuses on the development and commercialization of novel recombinant human enzymes for enhancing the delivery of biologics and drugs. It also offers drug delivery technology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Halozyme conducts research to advance its Enhanze platform to develop and manufacture product candidates for its partners. The company's Halozyme patent portfolio includes patents in the United States, Europe, and other parts of the world. It holds numerous patents and patent applications worldwide for its recombinant human hyaluronidase, methods of use and manufacture. The company’s ATRS – 1902, a drug device combination product for the endocrinology market is in Phase III trials. It has been granted fast-track designation by the FDA. The company operates a research facility in San Diego, California, the US. In FY2022, the company spent US$66.6 million on its R&D activities, which as a percentage of revenue stood at 10.1%, and grew 86.7% YoY.